Vifor Pharma Group
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vifor Pharma Group
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.
Vifor Pharma is still hoping for further clinical data to help differentiate its potassium binder Veltassa in the competitive hyperkalemia market after recruitment into its Phase IIIb DIAMOND study was slowed by COVID-19-related changes to clinical practice, necessitating a new primary endpoint.
Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
- Galenica Group
- Relypsa, Inc.
- Vifor Pharma
- Vifor-Fresenius Medical Care Renal Pharma Ltd.
- OM Pharma